Multichain protein biotherapeutics such as bispecific molecules have been developed to treat cancer, neurological and ophthalmic disorders, and autoimmune and inflammatory diseases. Early successes now are driving greater numbers of such molecules toward clinical evaluation and commercial approval. However, the complexity of bispecific development and manufacture calls for innovative tools and technologies to facilitate the clinical journeys of such products and prevent costly setbacks for their sponsors. In its commitment to fostering novel biomolecular formats, Lonza has designed a chemistry,…
Wednesday, November 16, 2022 Daily Archives
Bridgewest picks up another Pfizer plant down under
Private investment firm Bridgewest Group has signed a definitive agreement to buy Pfizer’s sterile injectable manufacturing facility in Western Australia. Pfizer’s manufacturing facility is located in Bentley, a Perth suburb in Western Australia. The plant is authorized to supply drug products in over 90 countries across the globe and approvals have been granted by various regulatory bodies, including the Food and Drug Administration (FDA), Therapeutic Goods Administration (TGA), and the European Union (EU). According to Bridgewest, the facility has blow…
Second Irish site aims to enhance biopharma’s security of supply, says Avantor
Avantor has opened a 69,000 square-foot storage and distribution site in Dublin, Ireland to serve biomanufacturers in the region. The facility, financials of which have not been divulged, will offer Avantor’s customers cGMP warehousing, on-site clean rooms, batch-to-batch traceability, custom palletization, inbound and outbound product quality inspections, and vendor managed inventory solutions. “This new facility will expand capacity in the country and streamline processes for our customers,” Ger Brophy, EVP of Biopharma Production at Avantor told BioProcess Insider. “We also…
Catalent mothballing recently bought UK plant
CDMO Catalent will delay bringing new capital expenditure projects in Oxford and Princeton, New Jersey online as it looks to keep utilization rates stable during the post-COVID period. Correction November 17: The original headline suggested Catalet was mothballing both the Oxford and Princeton site. While this is the case for the Oxford site, it is only the expanson at Princeton that is on hold and it continues to operate. Catalent expanded its manufacturing footprint in April this year after acquiring…